By Suherman Candra Maholtra 
A landmark study conducted by researchers at UVA Health’s Beirne B. Carter Center for Immunology Research and the UVA Comprehensive Cancer Center has revealed a significant correlation between severe respiratory viral infections, such as COVID-19 and influenza, and the accelerated development of lung cancer. The research, published in the prestigious journal Cell, suggests that the physiological aftermath of a severe infection can create a persistent "pro-tumor" environment within the respiratory system, potentially leading to oncological complications months or even years after the initial recovery. However, the study also highlights a critical preventative measure: vaccination, which appears to mitigate these long-term risks by preventing the severe immune dysregulation that fuels tumor growth.
Led by Jie Sun, PhD, a scientist at the UVA School of Medicine and co-director of the Carter Center, the research team discovered that the damage caused by high-severity viral pneumonia is not merely a short-term hurdle for the body to overcome. Instead, severe bouts of respiratory illness can fundamentally alter the landscape of the lungs. These alterations involve the permanent or long-lasting modification of immune cells, which, rather than returning to a state of surveillance and defense, begin to foster conditions that allow cancer cells to take root and proliferate.
The Biological Mechanism of Immune Scarring
To understand how a virus can influence cancer development, the UVA team focused on the behavior of specific immune cells—neutrophils and macrophages—following a severe infection. In a healthy state, these cells are the body’s first line of defense, identifying and destroying pathogens. However, the study’s findings in laboratory mice demonstrated that after a severe respiratory infection, these cells undergo a transformation.
Specifically, certain neutrophils began to exhibit abnormal behavior, contributing to a chronic state of inflammation. This environment, described by researchers as "pro-tumor," essentially provides a fertile ground for malignant cells. Furthermore, the study observed significant changes in the epithelial cells that line the lungs and the alveoli—the tiny air sacs responsible for gas exchange. This "immune scarring" suggests that the lungs do not simply heal after a severe infection; they are often left in a compromised state that is more susceptible to secondary pathologies, including lung cancer.
The research indicates that the severity of the initial infection is the primary driver of this risk. While mild cases of COVID-19 or influenza did not appear to increase cancer incidence—and in some instances, were associated with a slight decrease—severe cases that required hospitalization or led to pneumonia were the clear catalysts for these dangerous cellular shifts.
Analyzing the Statistical Correlation: A 1.24-Fold Increase
The transition from laboratory observations to clinical reality was supported by an extensive analysis of human patient data. By examining the medical histories of individuals who had been hospitalized with COVID-19, the researchers identified a striking pattern. The data revealed a 1.24-fold increase in the incidence of lung cancer among patients who had survived severe COVID-19 compared to those who had not.
Crucially, this elevated risk was found to be independent of other traditional risk factors. Even when accounting for smoking history, age, and various comorbidities, the correlation between severe viral infection and subsequent lung cancer remained significant. This finding challenges the traditional understanding of lung cancer etiology, which has historically focused heavily on environmental toxins and genetic predispositions.
"We’ve known for a long time that things like smoking increase the risk for lung cancer," said Jeffrey Sturek, MD, PhD, a UVA physician-scientist and collaborator on the study. "The results from this study suggest that we may need to think about severe respiratory viral infection similarly."
The Chronology of Research and Post-Pandemic Implications
The timing of this study is particularly relevant as the world continues to navigate the long-term consequences of the COVID-19 pandemic. Since 2020, tens of millions of people globally have experienced severe respiratory distress due to SARS-CoV-2. The UVA research provides a potential roadmap for understanding the "sequelae"—the long-term conditions following an acute illness—that may emerge in the coming decade.
The chronology of the study began with observations of "Long COVID" patients who reported persistent lung issues. This led the team to investigate the deeper cellular changes occurring post-infection. By utilizing mouse models to simulate severe viral pneumonia and then cross-referencing those biological markers with large-scale human health databases, the researchers were able to build a comprehensive picture of the post-viral oncogenic process.
The implications for clinical care are immediate. The research suggests a need for a shift in how medical professionals monitor patients who have survived severe respiratory crises. Just as a history of heavy smoking triggers regular screenings, a history of hospitalization for viral pneumonia may eventually become a standard criterion for enhanced lung cancer surveillance.
Vaccination as a Critical Preventative Tool
Perhaps the most significant takeaway from the UVA study is the role of vaccination in preventing cancer-promoting lung changes. The researchers found that individuals who had been vaccinated prior to infection were largely protected from the "pro-tumor" immune shifts.
Vaccines function by priming the immune system to recognize and neutralize a virus more efficiently. This typically prevents the infection from reaching the level of severity required to cause significant lung injury and immune scarring. By keeping the infection mild, the vaccine indirectly prevents the cascade of cellular changes that lead to an increased cancer risk.
"The encouraging news is that vaccination largely prevents those harmful changes for cancer growth in the lung," Dr. Sun noted. This adds a new dimension to the public health argument for routine vaccination against influenza and COVID-19. Beyond preventing acute hospitalization and death, vaccines may serve as a long-term protective measure against the development of chronic diseases like cancer.
Expert Reactions and Institutional Mission
The findings have sparked discussions within the medical community regarding the intersection of infectious disease and oncology. Experts at the UVA Comprehensive Cancer Center—one of only 57 National Cancer Institute-designated comprehensive centers in the United States—emphasize that this research underscores the importance of interdisciplinary collaboration.
The study aligns with the mission of UVA’s Paul and Diane Manning Institute of Biotechnology, which seeks to accelerate the translation of laboratory discoveries into clinical treatments. By identifying the specific immune cells (neutrophils and macrophages) that turn "pro-tumor," scientists can now begin to investigate targeted therapies. These therapies might one day be used to "reset" the immune environment in the lungs of patients who have recovered from severe pneumonia, effectively neutralizing the cancer risk before a tumor can form.
"Our goal is to help doctors identify who may be at higher risk of lung cancer after a severe infection and develop targeted ways to prevent and treat lung cancer after prior pneumonia," Sun stated.
Future Directions in Lung Cancer Surveillance
As medical professionals digest these findings, the focus turns to the practical application of the data. The research team advocates for a proactive approach to patient monitoring. For individuals with a history of both smoking and severe respiratory infection, the argument for routine CT scans becomes even more compelling.
In the future, clinical guidelines may evolve to include "respiratory infection history" as a key metric in oncological risk assessment. This would allow for earlier detection of lung cancer, which is the most critical factor in improving survival rates. Currently, lung cancer is often diagnosed at advanced stages when treatment options are limited; catching it early through enhanced surveillance could save thousands of lives.
The study was a massive collaborative effort involving dozens of researchers and was supported by numerous grants from the National Institutes of Health (NIH), the American Lung Association, and various UVA fellowships. The breadth of funding and the number of contributing scientists reflect the complexity and importance of the work.
Conclusion: A New Understanding of Viral Impact
The research from UVA Health provides a sobering look at the long-term biological costs of severe viral infections while offering a clear path forward through prevention and vigilant clinical care. By demonstrating that severe COVID-19 and influenza can leave a lasting "inflammatory footprint" that facilitates cancer, the study reframes viral pneumonia as a potential precursor to chronic oncological challenges.
However, the power of vaccination stands out as a primary defense. Not only do vaccines protect against the immediate dangers of a virus, but they also safeguard the body’s internal environment against the long-term "immune scarring" that leads to cancer. As the global medical community continues to monitor the health of millions of COVID-19 survivors, this research will likely serve as a foundational text for new screening protocols and preventative strategies in the years to come.
